eplex RP3 Control M530; eplex RP3 Negative
Maine Molecular Quality Controls, Inc. · Decision date Oct 30, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 10/30/2026 for eplex RP3 Control M530 and eplex RP3 Negative, submitted by Maine Molecular Quality Controls, Inc. of Saco, Maine, under 510(k) number K263232. The device falls under the classification name Assayed External Control Material For Microbiology Nucleic Acid Amplification (NAT) Assays, regulation number 866.3920, with product code PMN and Microbiology as the regulation medical specialty and review panel. The application was received 09/16/2026.
SESE in the 510(k) pathway denotes clearance to market, not premarket approval. The record identifies the submission as a Traditional 510(k) that was not reviewed by a third party, was not a combination product, and had no authorized Predetermined Change Control Plan. The page does not state which components or changes were assessed, the predicate device, or any performance data, so the technical basis for the clearance remains unknown from this record.
The listed applicant contact and correspondent contact are both Joan Gordon at the same Saco address. No summary statement content is captured in the available text, and the page was last updated 11/09/2026.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Oct 30, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K263232
- Regulatory pathway
- 510(k) premarket notification
- Product code
- PMN
- Decision code
- SESE
- Decision date
- Oct 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Assayed External Control Material For Microbiology Nucleic Acid Amplification (Nat) Assays.
- Product code
- PMN
- FDA device class
- 2
FDA decision timeline
K263232 received
Application receipt date recorded by FDA.
K263232 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code PMN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| BioFire Defense, LLC | 510(k) clearance | Nov 4, 2026 | FDA | |
| Maine Molecular Quality Controls, Inc. | 510(k) clearance | Oct 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Maine Molecular Quality Controls, Inc.
- Headquarters
- Not reported
- Brand website
- mmqci.com
- FDA applicant address
- Saco, ME
Sources and methodology
- Original FDA record: K263232
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
